18 F-FDG葡萄糖代谢显像对非小细胞肺癌的诊断评估

Diagnosis and evaluation of 18 F-FDG glucose metabolism imaging in non-small cell lung cancer

目的探讨18 F-FDG符合线路SPECT/CT葡萄糖代谢显像对非小细胞肺癌的诊断及评估。方法回顾性分析82例肺部占位性病变患者,分组后行SPECT/CT检查,然后比较各组T/N值并作ROC曲线,最后抽取39例肺癌术后患者进行半年期回顾性调查。结果通过对良性和非小细胞癌的组别T/N进行数据处理,计算诊断阈值为3.835;鳞癌与良性病变T/N值阈值为7.065;腺癌与良性病变T/N值阈值为3.905。半年期回顾性调查中术后患者的死亡率达23.1%。结论18 F-FDG符合线路SPECT/CT显像的T/N值可以作为诊断肿瘤的依据。非小细胞肺癌患者中鳞癌T/N平均值明显高于腺癌。

Objective To investigate the clinical application of 18 F-FDG coincidence SPECT/CT glucose metabolism imaging in the diagnosis,evaluation and half-year survival of non-small cell lung cancer.Methods We retrospectively analysed 82 patients with pulmonary space-occupying lesions,and determined the corresponding T/N by SPECT/CT examination,then compared the T/N values of these groups.The ROC curve was made with SPSS 13.1.Finally,39 patients with lung cancer were enrolled in a semi-annual retrospective survey of mortality rate.Results Through data processing of patients with benign and non-small cell carcinoma T/N,the diagnostic threshold was calculated to be 3.835.The T/N threshold of squamous cell carcinoma and benign lesions was 7.065.The threshold of T/N for adenocarcinoma and benign lesions was 3.905.A semi-annual retrospective study of postoperative patients showed a mortality rate of 23.1%.Conclusion The T/N value of 18 F-FDG conforming to line SPECT/CT imaging can be used as a basis for diagnosing tumors.The average T/N of squamous cell carcinoma in patients with non-small cell lung cancer is significantly higher than that adenocarcinoma.